Pfizer-Allergan Leadership: Two Dealmakers In The Driver's Seat
This article was originally published in Scrip
Ian Read will remain CEO of Pfizer Inc. when it mergers with Allergan PLC through a $160bn transaction set to close during the second half of 2016, but Allergan's like-minded CEO Brent Saunders will be sitting beside him as Pfizer PLC's president and chief operating officer – raising questions of whether Saunders is being positioned as Read's eventual replacement.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.